Literature DB >> 11443730

Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.

A C Antoniou1, P D Pharoah, G McMullan, N E Day, B A Ponder, D Easton.   

Abstract

We used data from a population based series of breast cancer patients to investigate the genetic models that can best explain familial breast cancer not due to the BRCA1 and BRCA2 genes. The data set consisted of 1,484 women diagnosed with breast cancer under age 55 registered in the East Anglia Cancer registry between 1991-1996. Blood samples taken from the patients were analysed for mutations in BRCA1 and BRCA2. The genetic models were constructed using information on breast and ovarian cancer history in first-degree relatives and on the mutation status of the index patients. We estimated the simultaneous effects of BRCA1, BRCA2, a third hypothetical gene BRCA3, and a polygenic effect. The models were assessed by likelihood comparisons and by comparison of the observed numbers of mutations and affected relatives with the predicted numbers. BRCA1 and BRCA2 could not explain all the familial clustering of breast cancer. The best-fitting single gene model for BRCA3 was a recessive model with a disease allele frequency 24% and penetrance 42% by age 70. However, a polygenic model gave a similarly good fit. The estimated population frequencies for BRCA1 and BRCA2 mutations were similar under both recessive and polygenic models, 0.024 and 0.041%, respectively. A dominant model for BRCA3 gave a somewhat worse fit, although the difference was not significant. The mixed recessive model was identical to the recessive model and the mixed dominant very similar to the polygenic model. The BRCA3 genetic models were robust to the BRCA1 and BRCA2 penetrance assumptions. The overall fit of all models was improved when the known effects of parity on breast and ovarian cancer risks were included in the model-in this case a polygenic model fits best. These findings suggest that a number of common, low-penetrance genes with additive effects may account for the residual non-BRCA1/2 familial aggregation of breast cancer, but Mendelian inheritance of an autosomal recessive allele cannot be ruled out. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443730     DOI: 10.1002/gepi.1014

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  86 in total

1.  After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.

Authors:  J Cui; A C Antoniou; G S Dite; M C Southey; D J Venter; D F Easton; G G Giles; M R McCredie; J L Hopper
Journal:  Am J Hum Genet       Date:  2000-12-27       Impact factor: 11.025

2.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

3.  Oligogenic combinations associated with breast cancer risk in women under 53 years of age.

Authors:  Christopher E Aston; David A Ralph; Dominique P Lalo; Sharmila Manjeshwar; Bobby A Gramling; Daniele C DeFreese; Amy D West; Dannielle E Branam; Linda F Thompson; Melissa A Craft; Debra S Mitchell; Craig D Shimasaki; John J Mulvihill; Eldon R Jupe
Journal:  Hum Genet       Date:  2004-12-21       Impact factor: 4.132

4.  Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer.

Authors:  Andrei Anghel; Marius Raica; Catalin Marian; Sorin Ursoniu; Oana Mitrasca
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

5.  Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies.

Authors:  Mitchell H Gail
Journal:  Lifetime Data Anal       Date:  2007-12-06       Impact factor: 1.588

6.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

Authors:  Antonis C Antoniou; Olga M Sinilnikova; Jacques Simard; Mélanie Léoné; Martine Dumont; Susan L Neuhausen; Jeffery P Struewing; Dominique Stoppa-Lyonnet; Laure Barjhoux; David J Hughes; Isabelle Coupier; Muriel Belotti; Christine Lasset; Valérie Bonadona; Yves-Jean Bignon; Timothy R Rebbeck; Theresa Wagner; Henry T Lynch; Susan M Domchek; Katherine L Nathanson; Judy E Garber; Jeffrey Weitzel; Steven A Narod; Gail Tomlinson; Olufunmilayo I Olopade; Andrew Godwin; Claudine Isaacs; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Bohdan Górski; Tomasz Byrski; Tomasz Huzarski; Susan Peock; Margaret Cook; Caroline Baynes; Alexandra Murray; Mark Rogers; Peter A Daly; Huw Dorkins; Rita K Schmutzler; Beatrix Versmold; Christoph Engel; Alfons Meindl; Norbert Arnold; Dieter Niederacher; Helmut Deissler; Amanda B Spurdle; Xiaoqing Chen; Nicola Waddell; Nicole Cloonan; Tomas Kirchhoff; Kenneth Offit; Eitan Friedman; Bella Kaufmann; Yael Laitman; Gilli Galore; Gad Rennert; Flavio Lejbkowicz; Leon Raskin; Irene L Andrulis; Eduard Ilyushik; Hilmi Ozcelik; Peter Devilee; Maaike P G Vreeswijk; Mark H Greene; Sheila A Prindiville; Ana Osorio; Javier Benitez; Michal Zikan; Csilla I Szabo; Outi Kilpivaara; Heli Nevanlinna; Ute Hamann; Francine Durocher; Adalgeir Arason; Fergus J Couch; Douglas F Easton; Georgia Chenevix-Trench
Journal:  Am J Hum Genet       Date:  2007-10-16       Impact factor: 11.025

7.  Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

Authors:  Renan Gomes; Pricila da Silva Spinola; Ayslan Castro Brant; Bruna Palma Matta; Caroline Macedo Nascimento; Silvia Maria de Aquino Paes; Cibele Rodrigues Bonvicino; Anna Claudia Evangelista Dos Santos; Miguel Angelo Martins Moreira
Journal:  Breast Cancer Res Treat       Date:  2020-10-30       Impact factor: 4.872

8.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

9.  Predicting breast cancer risk: implications of a "weak" family history.

Authors:  Elaine Anderson; Jonathan Berg; Roger Black; Nicola Bradshaw; Joyce Campbell; Roseanne Cetnarskyj; Sarah Drummond; Rosemarie Davidson; Jacqueline Dunlop; Alison Fordyce; Barbara Gibbons; David Goudie; Helen Gregory; Kirstie Hanning; Susan Holloway; Mark Longmuir; Lorna McLeish; Vicky Murday; Zosia Miedzybrodska; Donna Nicholson; Pauline Pearson; Mary Porteous; Marta Reis; Sheila Slater; Karen Smith; Elizabeth Smyth; Lesley Snadden; Michael Steel; Diane Stirling; Cathy Watt; Catriona Whyte; Dorothy Young
Journal:  Fam Cancer       Date:  2008-06-17       Impact factor: 2.375

10.  No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers.

Authors:  Pål Møller; Lovise Maehle; Neal Clark; Jaran Apold
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.